News

Jun 06th 2017

Themis starts Phase II trial of Chikungunya vaccine in the U.S.


May 03rd 2017

Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO


More news

#ThinkBigger

 
 
 

Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.

 

Focus

Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in large markets.

 

Scope

Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €1m up to €10m over life of investment.

 

Funds

Managing and investing out of funds WP III and WP IV.

More than €200m AUM dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.